Fig. 2
From: Reciprocal regulation of TWIST1 and OGT determines the decitabine efficacy in MDS/AML
O-GlcNAcylation mediates DAC resistance by stabilizing TWIST1. A O-GlcNAc modification of TWIST1 detected by Co-IP and western blotting. Normal mouse IgG was used as negative control. B O-GlcNAc modification on TWIST1 in KG1a-DAC-R cells. C O-GlcNAc modification of TWIST1 in KG1a-TWIST1 cells after 20 ng/mL DAC treatment for 96 h. D, E TWIST1 expression in KG1a-TWIST1 cells treated with different concentrations of OSMI-1 (D) or PUGNAc (E) for 48 h. F, G TWIST1 level in KG1a-TWIST1 cells treated with 10 μg/mL OSMI-1 (F) or 100 μM PUGNAc (G) at indicated times. H, I TWIST1 level in KG1a-TWIST1 after 10 μg/mL OSMI-1(H) or 100 μM PUGNAc (I) treatment for 48 h and 1 μM CHX treatment for indicated times. J, K Ubiquitination of TWIST1 in KG1a-TWIST1 cells under 10 μg/mL OSMI-1 (J) or 100 μM PUGNAc (K) treatment. L TWIST1 level in KG1a-TWIST1 cells treated with 10 μg/mL OSMI-1, 1 μM CHX and 5 μM MG132 or 0.5 μM Baf-1 for 48 h. M TWIST1 level in KG1a-TWIST1 cells treated with 100 μM PUGNAc, 1 μM CHX and 5 μM MG132 or 0.5 μM Baf-1 for 48 h